US Stock MarketDetailed Quotes
ENLV Enlivex Therapeutics
- 1.300
- 0.0000.00%
Close Dec 4 16:00 ET
- 1.300
- 0.0000.00%
Post 20:02 ET
28.59MMarket Cap-1326P/E (TTM)
1.347High1.160Low796.16KVolume1.300Open1.300Pre Close1.00MTurnover4.95%Turnover RatioLossP/E (Static)21.99MShares4.59052wk High1.08P/B20.92MFloat Cap0.81052wk Low--Dividend TTM16.10MShs Float44.900Historical High--Div YieldTTM14.35%Amplitude0.810Historical Low1.260Avg Price1Lot Size
Enlivex Therapeutics Stock Forum
Sign in to post a comment
Note: The presence of 30 stock picks reflects the reality that not all stocks respond to their press releases immediately. For instance, today’s market activity saw certain high-performing stocks overshadow promising PRs, suggesting that it may take a day, several days, or even a week for the market to fully digest and react. I encourage you to save the watchlist I p...
28
7
6
$Enlivex Therapeutics (ENLV.US)$
Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
Tuesday, 3rd December at 8:30 am
Nes-Ziona, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV, the "Company")), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive interim efficacy data from the Phase I stage of its randomized, multi-country Phase I/II Allocetra™ tri...
Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
Tuesday, 3rd December at 8:30 am
Nes-Ziona, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ: ENLV, the "Company")), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive interim efficacy data from the Phase I stage of its randomized, multi-country Phase I/II Allocetra™ tri...
3
$Enlivex Therapeutics (ENLV.US)$ Benzinga· 1 min ago
Enlivex Board Approves Purchase Of Up To $1M Of Bitcoin
Enlivex Board Approves Purchase Of Up To $1M Of Bitcoin
$Enlivex Therapeutics (ENLV.US)$
Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis
Enlivex Therapeutics has initiated a Phase I clinical trial evaluating Allocetra™ in patients with psoriatic arthritis. The first patient has completed dosing and initial follow-up with no safety concerns reported. The trial aims to recruit six patients who haven't responded adequately to conventional therapies. The study wi...
Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis
Enlivex Therapeutics has initiated a Phase I clinical trial evaluating Allocetra™ in patients with psoriatic arthritis. The first patient has completed dosing and initial follow-up with no safety concerns reported. The trial aims to recruit six patients who haven't responded adequately to conventional therapies. The study wi...
$Enlivex Therapeutics (ENLV.US)$
Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
$Enlivex Therapeutics (ENLV.US)$
Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
$Enlivex Therapeutics (ENLV.US)$
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
Nes-Ziona, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the independent Data and Safety Monitoring Board (DSMB) has completed an interim data review at...
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
Nes-Ziona, Israel, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the independent Data and Safety Monitoring Board (DSMB) has completed an interim data review at...
$Enlivex Therapeutics (ENLV.US)$ I just got another alert look at the spike in the past 5 minutes does anybody follow this company here at all can anybody provide any insight cuz I'm going to be freaking sick if tomorrow it's opens up at like 3 and 1/2 $4 something stupid
2
1
$Enlivex Therapeutics (ENLV.US)$ I've been watching this all morning and all it's doing is upticking this is the second day in the row, look at the chart I know nothing about the company but I got an alert it looks like it's one of these stupid stocks that's going to go vertical
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
AhmadFH : Thanks Jag
71580478 : love it, thanks! what do you think about SHIM?
JMK47 : thanks for all your effort
101628821 : Is it going to melt or continue to rise today?
101821671 : Do you have any opinions on the stock symbol SOAR?
View more comments...